(ii) A represents O, S or a sulfur atom oxidized to a sulfoxide;

(iii) the cyclic group labeled F represents an unsubstituted C_6 or C_{10} aryl or a C_5 heteroaryl group having nitrogen as a heteroatom or a phenyl group substituted with ethoxycarbonyl function; and

(iv) Y represents the group



wherein R_2 and R_3 are independently hydrogen; or methyl or ethyl;
or Y represents the group CH_3, or $(CH_2)_2CH_3$ or an unsubstituted C_5 heteroaryl group having nitrogen as a heteroatom.

B1

34. The compound of claim 33 wherein R_1 is an unsubstituted 1-naphthyl group.

35. The compound of claim 33 wherein F is an unsubstituted phenyl group or an unsubstituted naphthyl or 2,3-pyridine.

36. The compound of claim 33 wherein R_1 and F represent a 1-naphthyl group and a 2,3-naphto-fused group, respectively.

37. The compound of claim 33 wherein Y is selected from the group consisting of CH_3 or $N(Me)_2$, NHMe or a 4-pyridine group.

38. A compound of claim 33 selected from the group consisting of:
4-Acetoxy-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,
7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,
4[(Dimethylcarbamoyl)oxy]-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,
7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d] [1,5]benzoxazepine,

7-[(Methylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]-benzoxazepine,

7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,

7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,

7-Acetoxy-6-(1-naphthyl)pyrrolo[1,2-d]pyrido[3,2-b][1,4]oxazepine,

4-Acetoxy-5-(1-naphthyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,

4-[(Dimethylcarbamoyl)oxy]-5-(1-naphthyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4] oxazepine, 7-[(Ethylcarbamoyl)oxy]-6-phenylpyrrolo[2,1-d][1,5]benzoxazepine,

7-[(Methylcarbamoyl)oxy]-6-phenylpyrrolo[2,1-d][1,5]benzoxazepine,

7-Isonicotinoyloxy-6-(p-methoxyphenyl)pyrrolo [2,1-d][1,5]benzothiazepine, or

7-(Butyryloxy)-6-(p-methoxyphenyl)pyrrolo[2,1-d][1,5]benzothiazepine 5-oxide.

39. A pharmaceutical composition comprising the compound of claims 33-38 and a pharmaceutically acceptable carrier.

40. A method for selective apoptosis in cancerous cell lines comprising administering to a subject in need thereof, a pharmaceutically effective amount of a compound of formula I



wherein:

(i) R_1 represents an unsubstituted C_6 or C_{10} aryl group; or a C_6 aryl group substituted with Me or OMe;

(ii) A represents O, S; or a sulfur atom oxidized to sulfoxide;

(iii) the cyclic group labeled F represents an unsubstituted C_6 or C_{10} aryl or a C_5 heteroaryl group having nitrogen as a heteroatom or a phenyl group substituted with ethoxycarbonyl function; and

(iv) Y represents the group



wherein R_2 and R_3 are independently hydrogen; or methyl or ethyl;
or Y represents the group CH_3; or $(CH_2)_2CH_3$ or an unsubstituted C_5 heteroaryl group having nitrogen as a heteroatom; and
assessing the affects of the administration.

41. A method of claim 40 wherein the compound is selected from the group consisting of:
4-Acetoxy-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,
7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,
4[(Dimethylcarbamoyl)oxy]-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,
7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,
7-[(Methylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]-benzoxazepine,
7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][l,5]benzothiazepine,
7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,
7-Acetoxy-6-(1-naphthyl)pyrrolo[1,2-d]pyrido[3,2-b][1,4]oxazepine,
4-Acetoxy-5-(1-naphthyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,
4-[(Dimethylcarbamoyl)oxy]-5-(1-naphthyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4] oxazepine, 7-[(Ethylcarbamoyl)oxy]-6-phenylpyrrolo[2,1-d][1,5]benzoxazepine,
7-[(Methylcarbamoyl)oxy]-6-phenylpyrrolo[2,1-d][1,5]benzoxazepine,
7-Isonicotinoyloxy-6-(p-methoxyphenyl)pyrrolo[2,1-d][1,5]benzothiazepine,
7-(Butyryloxy)-6-(p-methoxyphenyl)pyrrolo[2,1-d][1,5]benzothiazepine 5-Oxide.

42. The method of claim 40 wherein the subject is a human or animal.

43. The method of claim 40 wherein the cancerous cell lines are selected from the

group consisting of leukemic T cell lymphoblast cells (Jurkat), promyelocytic leukemia cells (HL-60), T-cell leukemia cells (Hut-78), chronic myeloid lymphoma cells (CML), T lymphoblastoid cells (CEM), cervix carcinoma cells (HeLa) and human breast carcinoma cells (MCF-7).

44. The method of claim 43 wherein the chronic myeloid lymphoma cells are selected from the group consisting of LAMA, KYO.1 and K562 cell lines.

REMARKS

Claims 20-32 have been cancelled without prejudice or disclaimer. New claims 33-44 have been added. No new matter has been added by virtue of the within amendments. For example, support for new claims 33-44 can be found throughout the specification and in the original claims of the application.

Claims 20-25 stand rejected under 35 USC §112, 2nd paragraph. As the Office Action is understood, objection is made to the language "for inducing apoptosis" as it appears in claim 20.

While Applicants believe that the noted claims are abundantly clear and definite, it is believed that the within amendments obviate the rejection. In particular, claim 20 has been cancelled and the subject matter of claim 20 is now recited in new claims 33 and 39.

Reconsideration and withdrawal of the afore-mentioned rejection are thus requested.

Claims 26 and 29-31 stand rejected under 35 USC §112, 1st paragraph. As the Office Action is understood, claim 26 is rejected on the grounds that its utility is allegedly too broadly stated. Further, claims 29-31 stand rejected on the grounds that the treatment of all tumors allegedly is not adequately supported by the specification in the present application.

While Applicants believe that the specification amply supports and enables such